A novel drug design approach against cancer targets
Most small-molecule drugs against proteins usually target a regulatory moiety or the enzymatic active centre. However, there are molecular targets where this strategy cannot be implemented. The EU-funded E3glueRBP project proposes to address this issue through small molecules that induce interaction between two proteins and cause degradation of the disease-associated target. The team will develop a platform that utilises computational and biochemical methods to predict such protein domains and design appropriate molecular inhibitors. Project results will advance the field of cancer drug development and expand current therapeutic opportunities.